NKTR Deadline: Rosen Law Firm Urges Nektar Therapeutics (NASDAQ: NKTR) Stockholders to Contact the Firm for Information About Their RightsApril 27, 2026
Share Twitter Facebook LinkedIn Email The strategy worked when cars were in short supply during the post-COVID chip crisis, but buyers now have the advantage. Renault and Mercedes have warned that lower pricing power could undercut profits.Read More